Determining the mutational status of NPM1 (and FLT3) is a necessary step for the genetic-based risk categorization of AML, according to the updated 2022 European Leukemia Net (ELN) guidelines [26]. This evidence concerns the gene NPM1 and acute myeloid leukemia.